Title:
FUSION PROTEIN
Document Type and Number:
WIPO Patent Application WO/2024/005204
Kind Code:
A1
Abstract:
Provided is a novel protein, or the like, as a trispecific tribody in which antitumor effects have been augmented. The present invention relates to a fusion protein comprising a first chain and a second chain which are different from one another. Three types of combined VH/VL binding domains formed in the fusion protein have any one binding capability selected from: (i) a binding capability with respect to 5T4; (ii) a binding capability with respect to a T-cell CD3 receptor complex; and (iii) a binding capability with respect to PD-1, PD-L1, or LAG3 (note that the three types of combined VH/VL binding domains all have binding capabilities different from one another).
More Like This:
Inventors:
NAKAMURA KOJI (JP)
HASHIMOTO SHUICHI (JP)
YOSHIOKA ASAMI (JP)
TAKAHASHI KOTA (JP)
INOUE TOSHIKAZU (JP)
SANO HITOMI (JP)
DE LORENZO CLAUDIA (IT)
PASSARIELLO MARGHERITA (IT)
HASHIMOTO SHUICHI (JP)
YOSHIOKA ASAMI (JP)
TAKAHASHI KOTA (JP)
INOUE TOSHIKAZU (JP)
SANO HITOMI (JP)
DE LORENZO CLAUDIA (IT)
PASSARIELLO MARGHERITA (IT)
Application Number:
PCT/JP2023/024487
Publication Date:
January 04, 2024
Filing Date:
June 30, 2023
Export Citation:
Assignee:
CHIOME BIOSCIENCE INC (JP)
CEINGE BIOTECNOLOGIE AVANZATE FRANCO SALVATORE SCARL (IT)
CEINGE BIOTECNOLOGIE AVANZATE FRANCO SALVATORE SCARL (IT)
International Classes:
C12N15/62; A61K39/395; A61P35/00; C07K16/28; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/13; C12N15/63; C12P21/08
Foreign References:
| JP2021518168A | 2021-08-02 | |||
| JP2018500025A | 2018-01-11 |
Other References:
"Cancer treatment antibody CBA-1535 begins the world's first clinical trial as a Tribody antibody", CHIOM NEWSLETTER, 9 June 2022 (2022-06-09), XP093124782, Retrieved from the Internet [retrieved on 20240129]
MERTENS NICO: "Tribodies: Fab-scFv Fusion Proteins as a Platform to Create Multifunctional Pharmaceuticals", BISPECIFIC ANTIBODIES, SPRINGER, DE, 1 January 2011 (2011-01-01), DE , pages 135 - 149, XP009189923, ISBN: 978-3-642-20909-3
PASSARIELLO MARGHERITA, YOSHIOKA ASAMI, TAKAHASHI KOTA, HASHIMOTO SHU-ICHI, INOUE TOSHIKAZU, NAKAMURA KOJI, DE LORENZO CLAUDIA: "Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 41, no. 1, 1 January 2022 (2022-01-01), XP093028035, DOI: 10.1186/s13046-022-02474-3
MERTENS NICO: "Tribodies: Fab-scFv Fusion Proteins as a Platform to Create Multifunctional Pharmaceuticals", BISPECIFIC ANTIBODIES, SPRINGER, DE, 1 January 2011 (2011-01-01), DE , pages 135 - 149, XP009189923, ISBN: 978-3-642-20909-3
PASSARIELLO MARGHERITA, YOSHIOKA ASAMI, TAKAHASHI KOTA, HASHIMOTO SHU-ICHI, INOUE TOSHIKAZU, NAKAMURA KOJI, DE LORENZO CLAUDIA: "Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 41, no. 1, 1 January 2022 (2022-01-01), XP093028035, DOI: 10.1186/s13046-022-02474-3
Attorney, Agent or Firm:
KOBAYASHI Hiroshi et al. (JP)
Download PDF: